

# OLAF PENACK

## Short scientific biography

Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for many patients with hematologic malignancies. However, survival after HSCT is <50% because patients die frequently from graft-versus-host disease (GVHD) or tumor relapses. Novel therapeutic approaches are urgently needed to improve survival. Recent research has identified the endothelium as a therapeutic target in GVHD as well as in tumors. My laboratory works with pre-clinical murine HSCT models and our main aims are: 1) to better understand the function of the endothelium during HSCT, and 2) to develop endothelium based therapies after HSCT.